Overview: Leukemia CLL HCL SLL Panel
Introduction: The Leukemia CLL HCL SLL Panel is a diagnostic tool designed to diagnose CLL, HCL, and SLL using whole blood or bone marrow samples. In India, CLL is the most common adult leukemia (~4-5 per 100,000 elderly), with HCL and SLL rarer but treatable with targeted agents (ibrutinib, cladribine). High morbidity from under-testing in rural/low-SES elderly with lymphocytosis or splenomegaly, limited flow labs, delayed therapy leading to infections or progression. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs flow cytometry and PCR for 34 CLL/HCL/SLL markers (CD5, CD19, CD23, CD43, CD11c, CD25, CD103, etc.) over 1-2 days with high accuracy, valuable for immunophenotypic classification (CD5+/CD23+ in CLL, CD103+/CD25+ in HCL). This diagnostic falls under leukemia screening and targets patients with persistent lymphocytosis or lymphadenopathy, addressing accurate detection to guide watch-and-wait, BTK inhibitors, or purine analogs. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise subtype diagnosis and improving outcomes. Its blood/bone marrow-based approach ensures reliable marker analysis.
Other Names: CLL HCL SLL Pnl.
FDA Status: FDA approved, CLIA certified for molecular pathology/hematology/oncology/cytogenetics, compliant with 2025 standards.
Historical Milestone: CLL/HCL flow panel standard; in India, used in hematology labs.
Purpose: The test assesses 34 parameters including CLL markers to guide diagnosis of CLL/HCL/SLL, classify immunophenotype, inform therapy.
Test Parameters: 1â€"34. CLL Markers (CD5, CD19, CD23, CD43, etc.).
Pretest Condition: No fasting required; patients should have lymphocytosis or nodes.
Specimen: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for flow/PCR).
Medical History: Patients should provide details on lymphocytosis, fatigue, infections.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed CLPD including progression, benefits of profiling, and minimal discomfort from sampling.
Procedural Considerations: The test involves sample processing using flow cytometry/PCR by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low cell count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: CD5+/CD23+ confirms CLL; CD103+/CD25+ confirms HCL, necessitating specialist input.
Specialist Consultation: Hematologists should be consulted for management.
Additional Supporting Tests: Cytogenetics, IgVH for confirmation.
Test Limitations: Requires viable cells; comprehensive approach required.
References: Indian Journal of Hematology 2024, Leukemia Studies India 2023.
